Merck & Co has signed a licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) that will allow more companies to manufacture generic versions of its experimental oral antiviral COVID-19 treatment, the U.S. drugmaker and the organization announced on Wednesday.
The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermidhas signed a licensing agreement with the United Nations-backed Medicines Patent Pool that will allow more companies to manufacture generic versions of its experimental oral antiviral COVID-19 treatment, the U.S. drugmaker and the organization announced on Wednesday.
The U.S. Food and Drug Administration is considering emergency use authorization of the medicine, which was shown in"This is the first transparent, public health-driven voluntary license for a COVID-19 medical technology," Merck and MPP said in a joint statement. Medical charity Medecins Sans Frontieres , however, expressed disappointment with the limitations of the license as its territory excludes nearly half of the world's population and upper-middle-income countries with robust manufacturing capacities, such as Brazil and China.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Covid-19: Record case rates in Wales and long Covid study begins in ScotlandFive things you need to know about the coronavirus pandemic this Tuesday evening.
Les mer »
U.S. drug company Merck to share license for experimental covid-19 treatment with non-profitU.S. pharmaceutical giant Merck has agreed to share its license with a non-profit so that its experimental covid-19 drug, molnupiravir, can be manufactured widely around the world in a deal that would expand access in more than 100 countries
Les mer »
Moderna Data Shows Covid-19 Vaccine Produced Strong Immune Response in 6- to 11-Year-OldsModerna said it would submit the results from an interim study to health regulators in the U.S., Europe and elsewhere in seeking authorization for 6- to 11-year-olds.
Les mer »
Moderna Says Its Low-Dose COVID-19 Vaccine Works For Kids 6 To 11Children who received the vaccine developed virus-fighting antibodies similar to levels that young adults produce after full-strength shots, Moderna said.
Les mer »
Moderna says its COVID-19 vaccine is protective, safe in kids 6 to 11Moderna said its two-dose vaccine generated virus-neutralizing antibodies in children and safety was comparable to what was previously seen in clinical trials of adolescents and adults.
Les mer »
EU regulator starts real-time review of Merck's COVID-19 pillU.S. drugmaker Merck & Co Inc said on Monday the European Union's drug regulator has initiated a real-time review of its experimental COVID-19 antiviral drug for adults.
Les mer »